1 / 27

WHO workshop on

WHO workshop on Quality, good manufacturing practice and bioequivalence with a focus on antituberculotics Jiaxing, China 5 to 9 November 2007. Introduction to: Dossier requirements and guidelines for generics (quality part). Theo Dekker, D.Sc. Research Institute for Industrial Pharmacy

umay
Download Presentation

WHO workshop on

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHO workshop on Quality, good manufacturing practice and bioequivalence with a focus on antituberculotics Jiaxing, China 5 to 9 November 2007 Introduction to: Dossier requirements and guidelines for generics (quality part) Theo Dekker, D.Sc. Research Institute for Industrial Pharmacy North-West University, Potchefstroom, South Africa

  2. The patient matters The joint efforts of WHO, manufacturers, procurement agencies & other role players should coverall activities aimed at ensuring thatthe patient receives a product that meets established standards of efficacy, safety & quality

  3. Abbreviations GMP Good manufacturing practices ICH International Conference onHarmonization PhEurEuropean Pharmacopoeia PhInt International Pharmacopoeia PIL Patient information leaflet PQIF Pharmaceutical quality information form SmPC Summary of product characteristics TB Tuberculosis USP United States Pharmacopeia API Active pharmaceutical ingredient APIMF API master file BCS Biopharmaceutics classification system BE Bioequivalence BP British Pharmacopoeia CEP Certificate of suitability (Ph.Eur.) CPP WHO-type Certificate of a Pharmaceutical Product EOIExpression of interest FDC Fixed-dose combination FPP Finished pharmaceutical product

  4. Objective To give brief overview of • Guidelines used in Prequalification Programme The guidelines are important for • Product development • Safety, efficacy & quality • Preparation of submissions, for example • Dossier • PQIF (Pharmaceutical Quality Information Form) • BTIF (Bioequivalence Trial Information Form) • Good manufacturing practices (GMP) • Good laboratory practices (GLP of BE studies)

  5. Where to find ? All information on the Prequalification Program? e.g. • Guidelines • Other training material on prequalification • Very useful for • applicants and regulators • Also • Current invitation for expression of interest • Assessment meeting dates

  6. Prequalification Programme websitehttp://who.int/prequal/

  7. Focus – Quality aspects Multisource (generic) medicines • ForTuberculosis (TB) • Mainly first line TB medicines • Rifampicin, isoniazid, pyrazinamide & ethambutol hydrochloride • Mainly oral solid dosage forms • Emphasis on fixed-dose combinations (FDCs)

  8. Important definitions • Current WHO definitions • Used throughout the presentations

  9. WHO Technical Report Series 937 (2006) • Multisource (generic) pharmaceutical products • Pharmaceutically equivalentorpharmaceutically alternative products • that may or may not be therapeutically equivalent • Multisource pharmaceutical products that are therapeutically equivalent are interchangeable • Pharmaceutical equivalent products • Contain the same API(s) • in the same molar amount(s) • in the same dosage form • Meet similar quality standards • Are intended for the same route of administration… • May or may not be therapeutically equivalent

  10. WHO Technical Report Series 937 (2006) • Pharmaceutical alternative products contain • the same molar amount of the same active pharmaceutical moiety(s), but • differ in dosage form (e.g. tablets versus capsules) and/or • differ in chemical form (e.g. different salts, different esters). • Pharmaceutical alternatives • deliver the same active moiety by the same route of administration • but are otherwise not pharmaceutically equivalent • They may or may not be bioequivalent or therapeutically equivalent to the comparator product.

  11. Product ingredients • Active Pharmaceutical Ingredient (API) A substance or compound intended to be used in the manufacture of a pharmaceutical product as a therapeutically active compound (ingredient) • Excipient A substance or compound, other than the API and packaging materials, that is intended or designated to be used in the manufacture of a pharmaceutical product

  12. The product • Pharmaceutical Product Any preparation for human or veterinary use that is intended to modify or explore physiological systems or pathological states for the benefit of the recipient • Finished Pharmaceutical Product (FPP) A pharmaceutical product that has undergone all stages of production, including packaging in its final container & labelling

  13. Guideline on generics Main generic guideline • Guideline on submission of documentation for prequalification of multi-source (Generic) Finished Pharmaceutical Products (FPPs) used in treatment of HIV/AIDS, Malaria and Tuberculosis • with 8 annexes[under revision] • Supplement 1: Dissolution testing • Supplement 2: Extension of the WHO list of stable APIs (not easily degradable) [stability testing]

  14. Generic GuidelineAdministrative part A: Covering letter by responsible person • Statement: information is true and correct B: Application (requirements for productdossier) • Four main sections (with subsections) • Keep to the sections/subsections as prescribed • Sections/subsections should be clearly marked • preferably with securely fixed tags • Number all pages (essential) • Table of contents • List sections, subsections – with page numbers • Include Annexes 7 & 8(hard copy and CD-ROM)

  15. Generic guidelineDossier requirements – main sections Section 1 Characteristics of the FPP(3/26) Section 2 Active Pharmaceutical Ingredients (APIs) (4/26) Section 3 Finished Pharmaceutical Products (FPPs) (10/26) Section 4 Interchangeability (Bioequivalence) (25/26)

  16. Generic guidelineAnnexes (1 - 6) Annex 1: Model Certificate of a Pharmaceutical Product (CPP) Annex 2: Model Batch Certificate of Pharmaceutical Product Annex 3: Model Stability Report of API Annex 4: Model Stability Report of Capsules/Tablets Annex 5: Suggested Structure of the Summary of Product characteristics (SmPC) Annex 6: Suggested structure of the Package Information Leaflet (PIL)

  17. Generic guidelineAnnexes (7 & 8) Annex 7: Presentation of Bioequivalence Trial Information (BTIF)(Zip Word file) Annex 8: Presentation of Pharmaceutical Quality Information (PQIF) (Zip Word file) Applicant must properly complete BTIF and PQIF • Provide detailed & accurate information, referenced to dossier Submit with application / dossier the following: • Hard copy of BTIF and PQIF – original & duly signed • Electronic (Word) copy of each on CD-ROM BTIF and PQIF are used for assessment reports (CD-ROM)

  18. PQIF – example 1 Grey parts for assessors only ETH-400 Tablets Applicant fills out white parts Etambutol 400mg Tablets

  19. Main guidelineAnnex 8 (PQIF) – Example 2 1001 1001 1003 1002 1003 1002 1001 Ethambutol hydrochloride 80 80 80 400 4 4 4 20 Maize starch

  20. Example of mock-up PQIF On Prequalification website (by Dr. J. Pogány): • Training Workshop on Pharmaceutical Quality and Bioequivalence - Hanoi, Vietnam,  17 - 19 January 2006 • PQIF (API) • PQIF (FFP) Example shows how PQIF is: • filled out by applicant (typed in black) • assessed by first assessor (typed in red) • assessed by second assessor (typed in blue)

  21. Copy from mock-up PQIF

  22. Other guidelines on PQ website (1)Quality related • Guideline on Active Pharmaceutical Ingredient Master File (APIMF) Procedure • Implemented since January 2007 • Guidance on variations to a prequalified dossier • The prequalification process is dynamic, taking into account that changes to the original dossier may become necessary during the lifetime of the product • Any changes or variations are subject to approval within the prequalification program • Some variations are notifications

  23. Other guidelines on PQ website (2)Quality related • Guidelines for registration of fixed-dose combination medicinal products (TRS 943) • Innovators approved by ICH & associated DRAs • Guide on Submission of Documentation for Prequalification of Finished Pharmaceutical Products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis and approved by Drug Regulatory Authorities (DRAs) in the International Conference on Harmonization (ICH) region and associated countries, including inter alia the EU, Japan and USA

  24. ICH guidelines ICH guidelines are used when a quality aspect cannot be (fully) assessed by the WHO guidelines, for instance: • Q3A(R2). Impurities in new drug substances • Q3B(R2). Impurities in new drug products • Q3C(R3). Impurities: Guideline for residual solvents • Q6A. Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances (with decision trees)

  25. Closing remarks • The dossier submittedmust conform to the requirements set out in the current WHO guidelines, as posted on the Prequalification website • PQIF & BTIF (Word format) • APIMF procedure • The assessment of data is based on the current WHO guidelines • ICH guidelines are used when a quality aspect cannot be assessed by the WHO guidelines • The quality assessment includes variations orchanges to already prequalified products • Quality is built in by design, not tested in

  26. the patient matters

More Related